Page last updated: 2024-11-05

thalidomide and Retinal Neovascularization

thalidomide has been researched along with Retinal Neovascularization in 4 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Retinal Neovascularization: Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.

Research Excerpts

ExcerptRelevanceReference
"Diabetic retinopathy is an ocular complication associated with the chronic endocrine disorder of diabetes mellitus."6.55Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy. ( Behl, T; Goel, H; Kaur, I; Kotwani, A, 2017)
"Thalidomide is a well-known anti-angiogenic drug."5.35The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity. ( Katz, G; Pri-Chen, S; Rabinowitz, R; Rosner, M; Spierer, A, 2008)
"Diabetic retinopathy is an ocular complication associated with the chronic endocrine disorder of diabetes mellitus."2.55Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy. ( Behl, T; Goel, H; Kaur, I; Kotwani, A, 2017)
"Thalidomide has been shown to be anti-angiogenic via reduction of VEGF levels."1.36Intravitreal thalidomide reduces experimental preretinal neovascularisation without induction of retinal toxicity. ( Erber, R; Hammes, HP; Jonas, JB; Kamppeter, BA; Vom Hagen, F, 2010)
"Thalidomide is a well-known anti-angiogenic drug."1.35The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity. ( Katz, G; Pri-Chen, S; Rabinowitz, R; Rosner, M; Spierer, A, 2008)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Behl, T1
Kaur, I1
Goel, H1
Kotwani, A1
Dong, LF1
Yao, J1
Wang, XQ1
Shan, K1
Yang, H1
Yan, B1
Jiang, Q1
Vom Hagen, F1
Kamppeter, BA1
Erber, R1
Jonas, JB1
Hammes, HP1
Rabinowitz, R1
Katz, G1
Rosner, M1
Pri-Chen, S1
Spierer, A1

Reviews

1 review available for thalidomide and Retinal Neovascularization

ArticleYear
Significance of the antiangiogenic mechanisms of thalidomide in the therapy of diabetic retinopathy.
    Vascular pharmacology, 2017, Volume: 92

    Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Diabetic Retinopathy; Humans; Neovascularizat

2017

Other Studies

3 other studies available for thalidomide and Retinal Neovascularization

ArticleYear
Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder.
    Biochemical and biophysical research communications, 2015, Oct-02, Volume: 465, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line; Cell Movement; Cell Survival; Ch

2015
Intravitreal thalidomide reduces experimental preretinal neovascularisation without induction of retinal toxicity.
    The British journal of ophthalmology, 2010, Volume: 94, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Caspase 3; Down-Regulation; Intravitreal Injections; Mi

2010
The effect of thalidomide on neovascularization in a mouse model of retinopathy of prematurity.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2008, Volume: 246, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Dextrans; Disease Models, Animal; Fluoresceins;

2008